The Utility of Ga-DOTATATE Positron-emission Tomography/computed Tomography in the Diagnosis, Management, Follow-up and Prognosis of Neuroendocrine Tumors

Overview

Journal Future Oncol

Specialty Oncology

Date 2017 Oct 27

PMID 29072093

Citations 35

Authors

Amit Tirosh

Electron Kebebew

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine tumors (NETs) are rare neoplasms that emerge mainly from the GI tract, pancreas and respiratory tract. The incidence of NETs has increased more than sixfold in the last decades. NETs typically express somatostatin receptors on their cell surface, which can be targeted by 'cold' somatostatin analogs for therapy or by 'hot' radiolabeled somatostatin analogs for tumor localization and treatment. 68-Gallium-DOTA peptides (DOTATATE, DOTATOC, DOTANOC) positron emission tomography/computed tomography is a highly accurate imaging modality for NETs that has been found to be more sensitive for NET detection than other imaging modalities. In the current review, we will discuss the clinical utility of 68-Gallium-DOTATATE positron emission tomography/computed tomography for the diagnosis and management of patients with NETs.

Citing Articles

[Ga]‑DOTA‑conjugated somatostatin receptor‑targeting peptide PET for the differentiation between meningioma and glioblastoma: A case report and review of the literature.

Rauschenbach L, Gerach F, Berliner C, Blau T, Kebir S, Dobersalske C Oncol Lett. 2025; 29(4):199.

PMID: 40052066 PMC: 11883336. DOI: 10.3892/ol.2025.14945.

Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.

Ji X, Chen X, Li K, Zhang Z, Tang L, Li T Chem Biomed Imaging. 2024; 2(3):168-184.

PMID: 39474146 PMC: 11504603. DOI: 10.1021/cbmi.3c00093.

Deep-learning-based Attenuation Correction for Ga-DOTATATE Whole-body PET Imaging: A Dual-center Clinical Study.

Lord M, Islamian J, Seyyedi N, Samimi R, Farzanehfar S, Shahrbabki M Mol Imaging Radionucl Ther. 2024; 33(3):138-146.

PMID: 39373140 PMC: 11589349. DOI: 10.4274/mirt.galenos.2024.86422.

Two synchronous primary mesenteric neuroendocrine tumors in a patient: a case report.

Symeonidou E, Fouza A, Gkoutziotis I, Nikolaidou C, Petras P, Mpallas K Front Surg. 2024; 11:1323468.

PMID: 38638140 PMC: 11024421. DOI: 10.3389/fsurg.2024.1323468.

Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.

Liu Y, Cui R, Wang Z, Lin Q, Tang W, Zhang B Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543159 PMC: 10975134. DOI: 10.3390/ph17030373.

References

Sadowski S, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P . Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol. 2015; 34(6):588-96. PMC: 4872030. DOI: 10.1200/JCO.2015.64.0987. View

Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A . SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Mol Imaging Biol. 2014; 17(3):313-8. DOI: 10.1007/s11307-014-0795-3. View

Krenning E, Bakker W, Breeman W, Koper J, Kooij P, Ausema L . Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989; 1(8632):242-4. DOI: 10.1016/s0140-6736(89)91258-0. View

Kruger S, Buck A, Blumstein N, Pauls S, Schelzig H, Kropf C . Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med. 2006; 260(6):545-50. DOI: 10.1111/j.1365-2796.2006.01729.x. View

Kuyumcu S, Ozkan Z, Sanli Y, Yilmaz E, Mudun A, Adalet I . Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med. 2013; 27(6):538-45. DOI: 10.1007/s12149-013-0718-4. View

Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V . 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009; 30(4):281-6. DOI: 10.1097/MNM.0b013e32832999c1. View

Tirosh A, Stemmer S, Solomonov E, Elnekave E, Saeger W, Ravkin Y . Pasireotide for malignant insulinoma. Hormones (Athens). 2016; 15(2):271-276. DOI: 10.14310/horm.2002.1639. View

Nockel P, Babic B, Millo C, Herscovitch P, Patel D, Nilubol N . Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan. J Clin Endocrinol Metab. 2016; 102(1):195-199. PMC: 6083884. DOI: 10.1210/jc.2016-3445. View

Beiderwellen K, Poeppel T, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A . Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013; 48(5):273-9. DOI: 10.1097/RLI.0b013e3182871a7f. View

10.

Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B . 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013; 40(4):514-23. DOI: 10.1007/s00259-012-2309-3. View

11.

DAssignies G, Fina P, Bruno O, Vullierme M, Tubach F, Paradis V . High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013; 268(2):390-9. DOI: 10.1148/radiol.13121628. View

12.

Srirajaskanthan R, Kayani I, Quigley A, Soh J, Caplin M, Bomanji J . The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51(6):875-82. DOI: 10.2967/jnumed.109.066134. View

13.

Frilling A, Sotiropoulos G, Radtke A, Malago M, Bockisch A, Kuehl H . The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010; 252(5):850-6. DOI: 10.1097/SLA.0b013e3181fd37e8. View

14.

Pape U, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R . ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology. 2016; 103(2):144-52. DOI: 10.1159/000443165. View

15.

Falconi M, Eriksson B, Kaltsas G, Bartsch D, Capdevila J, Caplin M . ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016; 103(2):153-71. PMC: 4849884. DOI: 10.1159/000443171. View

16.

Perren A, Couvelard A, Scoazec J, Costa F, Borbath I, Delle Fave G . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology. 2017; 105(3):196-200. DOI: 10.1159/000457956. View

17.

Caplin M, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E . Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015; 26(8):1604-20. DOI: 10.1093/annonc/mdv041. View

18.

Haug A, Auernhammer C, Wangler B, Schmidt G, Uebleis C, Goke B . 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010; 51(9):1349-56. DOI: 10.2967/jnumed.110.075002. View

19.

Wolin E, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse M . Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015; 9:5075-86. PMC: 4562767. DOI: 10.2147/DDDT.S84177. View

20.

Werner R, Lapa C, Ilhan H, Higuchi T, Buck A, Lehner S . Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget. 2016; 8(4):7039-7049. PMC: 5351689. DOI: 10.18632/oncotarget.12402. View